183 related articles for article (PubMed ID: 8197647)
1. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
Lin BJ; Chen KK; Chen MT; Chang LS
Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
Maatman TJ; Gupta MK; Montie JE
J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
[TBL] [Abstract][Full Text] [Related]
3. Bilateral orchiectomy for carcinoma of prostate. Response of serum testosterone and clinical response to subsequent estrogen therapy.
Klugo RC; Farah RN; Cerny JC
Urology; 1981 Jan; 17(1):49-50. PubMed ID: 7456197
[TBL] [Abstract][Full Text] [Related]
4. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic prostate cancer. Factors that influence treatment selection and methods to increase acceptance of orchiectomy.
Merrill DC
Urology; 1988 Nov; 32(5):408-12. PubMed ID: 3188303
[TBL] [Abstract][Full Text] [Related]
6. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist.
Kitahara S; Yoshida K; Ishizaka K; Kageyama Y; Kawakami S; Tsujii T; Oshima H
Endocr J; 1997 Aug; 44(4):527-32. PubMed ID: 9447285
[TBL] [Abstract][Full Text] [Related]
7. Clamp ablation of the testes compared to bilateral orchiectomy as androgen deprivation therapy for advanced prostate cancer.
Zarrabi AD; Heyns CF
Int Braz J Urol; 2011; 37(3):347-54; discussion 354. PubMed ID: 21756382
[TBL] [Abstract][Full Text] [Related]
8. Rapid drop in serum testosterone after bilateral subcapsular orchiectomy.
Arcadi JA
J Surg Oncol; 1992 Jan; 49(1):35-8. PubMed ID: 1548879
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy.
Geller J; Albert JD; Nachtsheim DA; Loza D
J Urol; 1984 Oct; 132(4):693-6. PubMed ID: 6471215
[TBL] [Abstract][Full Text] [Related]
10. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
11. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view.
Bishop MC
Br J Urol; 1996 Dec; 78(6):921-7; discussion 927-8. PubMed ID: 9014720
[TBL] [Abstract][Full Text] [Related]
12. Plasma testosterone in patients receiving diethylstilbestrol.
Beck PH; McAnich JW; Goebel JL; Stutzman RE
Urology; 1978 Feb; 11(2):157-60. PubMed ID: 628992
[TBL] [Abstract][Full Text] [Related]
13. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
Krongrad A; Brady J; Rodriguez RJ
South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
[No Abstract] [Full Text] [Related]
14. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
Aggarwal R; Weinberg V; Small EJ; Oh W; Rushakoff R; Ryan CJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E71-6. PubMed ID: 19815485
[TBL] [Abstract][Full Text] [Related]
15. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma.
Tomić R; Bergman B
J Urol; 1987 Oct; 138(4):801-3. PubMed ID: 3116281
[TBL] [Abstract][Full Text] [Related]
16. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Soloway MS; Chodak G; Vogelzang NJ; Block NL; Schellhammer PF; Smith JA; Scott M; Kennealey G; Gau TC
Urology; 1991 Jan; 37(1):46-51. PubMed ID: 1824732
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer.
Ishikawa S; Soloway MS; Van der Zwaag R; Todd B
J Urol; 1989 May; 141(5):1139-42. PubMed ID: 2651713
[TBL] [Abstract][Full Text] [Related]
18. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
19. Relapse on endocrine treatment in patients with stage D2 prostate cancer. Does second-line hormonal therapy affect survival?
Matzkin H; Rangel MC; Soloway MS
Urology; 1993 Feb; 41(2):144-8. PubMed ID: 8497986
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
